128 related articles for article (PubMed ID: 14764461)
1. Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo.
Pennati M; Binda M; De Cesare M; Pratesi G; Folini M; Citti L; Daidone MG; Zunino F; Zaffaroni N
Carcinogenesis; 2004 Jul; 25(7):1129-36. PubMed ID: 14764461
[TBL] [Abstract][Full Text] [Related]
2. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression.
Pennati M; Binda M; Colella G; Folini M; Citti L; Villa R; Daidone MG; Zaffaroni N
J Invest Dermatol; 2003 Apr; 120(4):648-54. PubMed ID: 12648230
[TBL] [Abstract][Full Text] [Related]
3. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells.
Pennati M; Binda M; Colella G; Zoppe' M; Folini M; Vignati S; Valentini A; Citti L; De Cesare M; Pratesi G; Giacca M; Daidone MG; Zaffaroni N
Oncogene; 2004 Jan; 23(2):386-94. PubMed ID: 14724567
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of survivin expression enhances sensitivity of cultured uveal melanoma cells to cisplatin treatment.
Li H; Niederkorn JY; Neelam S; Alizadeh H
Exp Eye Res; 2006 Jul; 83(1):176-82. PubMed ID: 16584731
[TBL] [Abstract][Full Text] [Related]
5. Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3-mediated Bid cleavage.
Tomicic MT; Christmann M; Kaina B
J Pharmacol Exp Ther; 2010 Jan; 332(1):316-25. PubMed ID: 19812371
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo.
Zhang M; Mukherjee N; Bermudez RS; Latham DE; Delaney MA; Zietman AL; Shipley WU; Chakravarti A
Prostate; 2005 Aug; 64(3):293-302. PubMed ID: 15754318
[TBL] [Abstract][Full Text] [Related]
7. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
Wang Z; Sampath J; Fukuda S; Pelus LM
Cancer Res; 2005 Sep; 65(18):8224-32. PubMed ID: 16166298
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of survivin expression reversed multidrug resistance in adriamycin-resistant HL-60/ADR cell line.
Wang L; Zhang GM; Feng ZH
Acta Pharmacol Sin; 2003 Dec; 24(12):1235-40. PubMed ID: 14653950
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
10. [Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo].
Ji YB; Zhou JH; Zuo MX; You QD
Yao Xue Xue Bao; 2008 Aug; 43(8):811-8. PubMed ID: 18956773
[TBL] [Abstract][Full Text] [Related]
11. Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death.
Yamaguchi Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Saitou Y; Sugimoto K; Nakano T
Oncol Rep; 2005 Nov; 14(5):1311-6. PubMed ID: 16211302
[TBL] [Abstract][Full Text] [Related]
12. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q
Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125
[TBL] [Abstract][Full Text] [Related]
13. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of survivin-specific small interfering RNA and topotecan in renal cancer cells: topotecan enhances liposome-mediated transfection by increasing cellular uptake.
Sato A; Ito K; Asano T; Sumitomo M; Asano T; Hayakawa M
Int J Oncol; 2007 Mar; 30(3):695-700. PubMed ID: 17273771
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells.
Dong K; Wang R; Wang X; Lin F; Shen JJ; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Feb; 113(3):443-56. PubMed ID: 18327707
[TBL] [Abstract][Full Text] [Related]
16. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer.
Rödel F; Hoffmann J; Distel L; Herrmann M; Noisternig T; Papadopoulos T; Sauer R; Rödel C
Cancer Res; 2005 Jun; 65(11):4881-7. PubMed ID: 15930309
[TBL] [Abstract][Full Text] [Related]
17. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells.
Choi KS; Lee TH; Jung MH
Cancer Gene Ther; 2003 Feb; 10(2):87-95. PubMed ID: 12536196
[TBL] [Abstract][Full Text] [Related]
18. Topotecan and small interfering RNA suppress survivin expression synergistically in Caki-1 renal cancer cells: Direct suppression of survivin and enhancement of transfection efficiency by topotecan.
Sato A; Ito K; Asano T; Sumitomo M; Asano T; Hayakawa M
Int J Oncol; 2008 Jan; 32(1):171-6. PubMed ID: 18097556
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
Hideshima T; Catley L; Raje N; Chauhan D; Podar K; Mitsiades C; Tai YT; Vallet S; Kiziltepe T; Ocio E; Ikeda H; Okawa Y; Hideshima H; Munshi NC; Yasui H; Richardson PG; Anderson KC
Br J Haematol; 2007 Sep; 138(6):783-91. PubMed ID: 17760810
[TBL] [Abstract][Full Text] [Related]
20. Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin.
Jin HO; Yoon SI; Seo SK; Lee HC; Woo SH; Yoo DH; Lee SJ; Choe TB; An S; Kwon TJ; Kim JI; Park MJ; Hong SI; Park IC; Rhee CH
Biochem Pharmacol; 2006 Nov; 72(10):1228-36. PubMed ID: 16950207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
